Wisdomtree Global Quality Dividend Growth Ucits Etf Usd Inst (GGRI)

Regulus Integrates Innoviz LiDARs to Improve Counter-UAS Performance in Complex Operational Environments
June 30, 2026 8:00am EDT
https://ir.innoviz.tech/news-events/press-releases/detail/187/regulus-integrates-innoviz-lidars-to-improve-counter-uas

TEL AVIV, Israel, June

>

On the surface, the PR seems to claim that the latest "production cycle" produced 2.5 metric tons of cocoons. But we all know that the Serial Liar CEO exaggerates and lies on a continual basis.

The ques

.04+

My brain hurts trying to figure out how they do math. 

We are #1 on Most Read board again!

Cameco suspends Cigar Lake mining after acid plant outage disrupts ore processingJuly 1, 2026 7:12 AM
IH Market News

Wedbush initiates SpaceX with Outperform rating, sees AI and Starlink driving long-term growthJuly 1, 2026 7:10 AM
IH Market News

Klarna has received a favorable ruling in PriceRunner litigation, awarding damages of $1.97 billionJuly 1, 2026 7:19 AM
Business Wire Klarna Group plc (NYSE: KLAR) today announces that the court has ruled in PriceRunner’s favor, awarding $1.97 billion in damages in an antitrust

Implanting, I hope we get the move you mentioned. I wonder if our move back into the 40s wasn't that move and the next major one will come with further news? Let us hope we do get another move higher today. We'll find out in a couple of hours.

I gotta say, for everyone who has been

Quantum Leap: Why Wall Street Is Betting Big on IonQ

July 1, 2026

When you hear the phrase “quantum computing,” you might picture sci-fi labs and inscrutable equations. In reality, a handful of companies are already turning that futuristic hype into real hardware, and o

Quantum Leap: Why Wall Street Is Betting Big on IonQ

July 1, 2026

When you hear the phrase “quantum computing,” you might picture sci-fi labs and inscrutable equations. In reality, a handful of companies are already turning that futuristic hype into real hardware, and

$AABB Ongoing Share Buyback Program: $11,312,000 of AABB common shares as of March 31, 2026.

$AABB Ongoing Share Buyback Program: $11,312,000 of AABB common shares as of March 31, 2026.

IQM Quantum Computers and Real Asset Acquisition Corp. complete the combination; trading in IQM’s ADSs and IQM Warrants on Nasdaq Stock Market LLC commences on July 2, 2026

July 1, 2026

IQM Quantum Computers Plc ("IQM") has on February 22, 2026 entered into a definitive

JEM there it goes maybe

Interesting: I said to JM if there is no News by friday it doesn’t look good @ all … his reply: On the contrary … bizar as he was the one who messaged me saying … hope all will be wrapped by friday

It suddenly dawned on me this morning the reason for the PPS collapse during/after the conference call yesterday. It's the fear of an RS by a penny stock company. The first instinct for many shareholders is to sell. Unfortunately, this might remain an issue until the company decides what to do durin

IQM Quantum Computers and Real Asset Acquisition Corp. complete the combination; trading in IQM’s ADSs and IQM Warrants on Nasdaq Stock Market LLC commences on July 2, 2026

July 1, 2026

IQM Quantum Computers Plc ("IQM") has on February 22, 2026 entered into a definitive

You're arguing against a study for not proving something it never claimed to prove. The abstract explicitly states its purpose was "to evaluate tumors treated with a novel Y-90 hydrogel using PET-CT data measurements used for calculating decay curves" and to perform dosimetry and histopathology—not

https://x.com/i/status/2072168242555322518

All good things come to those who wait.

Will the big PAPER SHUFFLE BE FILED SOON???

https://investorshub.advfn.com/uimage/uploads/2019/10/23/kljymShuffling.jpg

Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026July 1, 2026 7:00 AM
Business Wire Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in

Neurogene Inc. Announces Pricing of $125 Million Public OfferingJuly 1, 2026 7:00 AM
Business Wire Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today ann